Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
Recent Articles
CMS Expands Access to CAR T-Cell Therapies Nationwide
The Centers for Medicare and Medicaid Services (CMS) will now provide “consistent and predictable” nationwide access to chimeric antigen receptor (CAR) T-cell therapies, according...
Doctors Rally to Support Disabled Indian Medical School Applicants in Legal Case
Doctors and medical groups from the U.S., U.K., and Australia expressed their opposition to a recent decision from the Medical Council of India (MCI)...
Immune Globulin Shortages Force Hospitals to Ration Treatments
A shortage of immune globulin (IG) is forcing hospitals to ration the drug and prioritize its use for patients who need it the most....
Hospitals and Drug Makers Provide Little Information on Patient DNA Collection
As gene sequencing becomes more common, hospitals and pharmaceutical companies have struck deals to collect and mine genetic information for drug development, but these...
Federal Authorities Question Ethics of “Pay-to-Play” Clinical Trials
The U.S. Food and Drug Administration (FDA) permits clinical trial sponsors to charge patients to participate in research in “extraordinary circumstances,” but, according to...
Current Issue
August 2019, Volume 5, Issue 10
This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.
